Amgen Announces Voting Results of Annual Meeting of Stockholders May 19, 2016 06:02PM
Amgen (AMGN) Will Present BLINCYTO, Kyprolis, Aranesp, and Nplate Data at EHA 2016 May 19, 2016 04:36PM
Amgen Highlights Data To Be Presented At 21st Congress Of The European Hematology Association May 19, 2016 04:34PM
Amgen (AMGN) Says Data to be Presented at ASCO Shows Insights Into Treatment Options For Patients May 18, 2016 05:10PM
Amgen Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients May 18, 2016 05:05PM
View Older Stories

May 17, 2016 04:00PM Amgen's Breakaway from Cancer® Public Service Announcement Delivers Message That Education, Resources And Hope Are Essential In The Fight Against Cancer
May 11, 2016 06:57AM Amgen (AMGN) Teams with NFL Legend Joe Montana for New 'Breakaway from Heart Disease' Campaign
May 11, 2016 06:45AM Hall of Fame Quarterback Joe Montana and Amgen Team Up to Launch Breakaway from Heart Disease™ to Make Heart Health a Priority
May 9, 2016 09:15AM Platelet BioGenesis Wins Amgen Golden Ticket For LabCentral
May 6, 2016 04:00PM Amgen To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
May 3, 2016 04:22PM Amgen's (AMGN) BLINCYTO sBLA Granted FDA Priority Review as Treatment of Certain ALL
May 3, 2016 04:21PM FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For BLINCYTO® (Blinatumomab)
Apr 28, 2016 04:01PM Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90
Apr 25, 2016 05:30PM Amgen Announces Webcast Of 2016 First Quarter Financial Results
Apr 25, 2016 09:00AM Amgen To Participate In The 2016 World Medical Innovation Forum™ On Cancer
Apr 19, 2016 04:01PM Amgen (AMGN) Says Study in The Lancet Shows Nplate Significantly Increases Durable Platelet Response
Apr 19, 2016 04:00PM Nplate® (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia
Apr 3, 2016 12:17PM Amgen (AMGN) Announces Publication of Positive Repatha Phase 3 GAUSS-3 Data
Apr 3, 2016 09:05AM Positive Efficacy And Tolerability Study Of Repatha® (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association"
Apr 1, 2016 04:01PM Amgen (AMGN), UCB Phase 3 Data Comparing Romosozumab With Teriparatide Presented at ENDO
Apr 1, 2016 04:00PM Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide
Mar 21, 2016 04:01PM Amgen (AMGN) Says 19 Abstracts Will be Presented at ACC
Mar 21, 2016 04:00PM Amgen To Present Repatha® (Evolocumab) Data At ACC.16
Mar 21, 2016 06:22AM Amgen (AMGN), UCB Announce Romosozumab Phase 3 Met Primary Endpoint in Men With Osteoporosis
Mar 21, 2016 01:00AM Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
Mar 16, 2016 02:02PM Amgen (AMGN) Comments Following Repatha Patent Win
Mar 16, 2016 02:00PM Amgen Wins Patent Case On Repatha® (Evolocumab)
Mar 16, 2016 12:33PM Regeneron (REGN) and Sanofi Confirm Negative Praluent Ruling, 'Strongly Disagree' with Verdict (AMGN)
Mar 10, 2016 04:00PM Amgen (AMGN) sBLA for Exapnded Enbrel Use Accepted by FDA
Mar 10, 2016 04:00PM FDA Accepts Amgen's Supplemental Biologics License Application For The Expanded Use Of Enbrel® (Etanercept) To Treat Pediatric Patients With Chronic Severe Plaque Psoriasis
Mar 3, 2016 04:00PM Amgen To Present At The Cowen And Company 36th Annual Health Care Conference
Mar 2, 2016 04:15PM Amgen Announces 2016 Second Quarter Dividend
Mar 1, 2016 04:01PM Amgen (AMGN) Submits sBLA For BLINCYTO
Mar 1, 2016 04:00PM Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab)
Feb 22, 2016 06:21AM Amgen (AMGN), UCB Announce FRAME Phase 3 Met co-Primary Endpoints; One Secondary Endpoint Missed
Feb 22, 2016 01:00AM Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Feb 16, 2016 06:50AM Amgen (AMGN) Announces Aranesp Phase 3 Met Primary Endpoint in MDS Red Blood Cell Transfusion Reduction
Feb 15, 2016 04:00PM Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)
Feb 5, 2016 05:06PM Amgen To Present At The Leerink Partners 5th Annual Global Healthcare Conference
Feb 5, 2016 07:51AM Amgen (AMGN) Announces BLINCYTO Phase 3 TOWER Met Primary Endpoint in r/r B-Cell Precursor ALL
Feb 4, 2016 04:17PM Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Feb 4, 2016 04:01PM Amgen (AMGN) Says Repatha Phase 3 GAUSS-3 Met co-Primary Endpoints
Feb 4, 2016 04:00PM Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Jan 28, 2016 04:00PM Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $10.38
Jan 25, 2016 05:21PM Amgen (AMGN) BLA for ABP 501 Accepted by FDA
Jan 25, 2016 05:20PM FDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501
Jan 25, 2016 04:03PM Amgen Announces Webcast of 2015 Fourth Quarter and Full Year Financial Results
Jan 25, 2016 06:16AM Amgen (AMGN) Announces Vectibix + BSC Phase 3 Met Primary Endpoint
Jan 23, 2016 01:00PM Vectibix® (panitumumab) And Best Supportive Care Improves Overall Survival Compared To Best Supportive Care In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer
Jan 22, 2016 06:18AM Amgen (AMGN) Announces Japanese Approval of Repatha as PCSK9 Inhibitor
Jan 22, 2016 01:00AM Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Jan 21, 2016 04:34PM Amgen (AMGN) Announces FDA Approval of Supplemental Kyprolis Combo NDA in r/r Multiple Myeloma
Jan 21, 2016 04:32PM FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Jan 7, 2016 04:05PM Amgen To Present At The 34th Annual J.P. Morgan Healthcare Conference
Dec 28, 2015 12:30PM Harris & Harris Group (TINY) Announces Receipt of BioVex Group-Related Milestone Payment
View Older Stories